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Abstract
Background: Recombinant peptide chips could constitute a versatile complementation to state-of-the-art in situ
(chemical on-chip) synthesis, particle-based printing, or pre-manufactured peptide spotting. Bottlenecks still
impeding a routine implementation - from restricted peptide lengths, low diversity and low array densities to high
costs - could so be overcome.
Methods: To assess overall performance, we assembled recombinant chips composed of 38,400 individual peptide
spots on the area of a standard 96-well microtiter plate from comprehensive, highly diverse (>107 single clones)
short random peptide libraries.
Results: Screening of altogether 476,160 clones against Streptavidin uncovered 2 discrete new binders: a
characteristic HPQ-motif containing VSHPQAPF and a cyclic CSGSYGSC peptide. Interactions were technically
confirmed by fluorescence polarization as well as biolayer-interferometry, and their potential suitability as novel
detection tags evaluated by detection of a peptide-fused exemplary test protein.
Conclusion: From our data we conclude that the presented technical pipeline can reliably identify novel hits,
useful as first-generation binders or templates for subsequent ligand design plus engineering.
Keywords: Peptide library, Recombinational cloning, Recombinant peptide array, Protein chip, Peptide screening,
Protein tags, Ligand design, High affinity, Target binding, Diversity
Background
Chips exposing precisely arranged spots of peptides on
top of a solid support constitute a fairly young alterna-
tive to widely implemented display [1, 2] or protein-
fragment complementation [3, 4] methods - each with
its unique strengths and weaknesses - for extracting
functional target binders from combinatorial peptide
libraries [5, 6]. Their popularity is at least in part attrib-
utable to the rising appreciation of peptides as starting
points for the design of novel therapeutics - ideally exhi-
biting favourable safety, tolerability plus efficacy profiles
by merging advantages of traditional small molecule
drugs (conformational constraints, membrane permeability,
oral bioavailability, metabolic stability, lower fabrication
complexity) with those of proteins (natural occurrence,
high target specificity/selectivity) [7]. As highlighted else-
where [8–11], peptide chips can in essence be assembled by
3 different procedures, namely parallel on-chip (photolith-
ography, SPOT concept) synthesis, particle-based printing,
or deposition of chemically pre-synthesized peptides. Fodor
and co-workers were amongst the first to convert Merri-
field solid phase peptide chemistry [12] to a chip format.
They introduced a set of photolabile ‘caps’ that only upon
selective laser illumination allowed for the liberation of the
N-terminus of a growing peptide chain, in this way making
it possible to exactly guide repetitive cycles of light-directed
de-protection, coupling, and washing away of unreacted
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monomers [13]. In contrast, the conceptually simpler, much
more popular SPOTapproach - launched by Frank and col-
leagues [14, 15] in continuing the previous achievements of
Geysen et al. [16] - delivers small volumes of pre-activated
amino acid (AA) solutions on a porous planar support
(classically functionalized cellulose filter paper). Absorbed
droplets create individual reaction compartments for subse-
quent parallel combinatorial peptide synthesis by standard
Fmoc (fluorenyl-methoxy-carbonyl) cleavage processes [11,
17]. Particle-mediated layer-by-layer ‘laser printing’ [18, 19],
next, relies on 20 different toner matrices that encapsulate
chemically activated, on-demand addressable building
blocks instead of regular colour pigments. When the latter
are deposited and heated up, all the solid microparticles at
once melt, triggering the release plus instantaneous coup-
ling of the hitherto matrix-arrested AA (with yields similar
to standard Merrifield synthesis). Spotted peptide chips,
lastly, make use of robotic microarrayers to (chemoselec-
tively) immobilize (nanolitre) volumes of pre-synthesized
(longer-chain) peptide solutions onto coherent substratum
[20, 21]. Solely this procedure offers the option to integrate
quality control in the manufacturing process, and might
under certain circumstances - e.g. when multiple copies of
the same chip are required - be more efficient as each mol-
ecules needs to be synthesized only once.
Features like utmost aptitude towards miniaturization,
multiplexing and automation equip this technology - ir-
respective of the underlying production method - with
far-reaching applications, tentatively only restrained by
combinatorial diversity plus realizable resolution. In-
corporation of modified or non-proteinogenic (synthetic)
segments during chip compilation furthermore offers
access to a much wider chemical space. In practice, how-
ever, limited synthesizable peptide lengths as well as
peptide numbers per area, inconsistent purities (accu-
mulation of side products) and prohibitively high costs
still impede a widespread adoption. The relatively small
liquid droplets in SPOT synthesis, for instance, tend to
either evaporate or merge with their neighbors, thus lim-
iting manageable densities to 9 to maximally 25 peptides
per cm2. Lithographic policies, in comparison, support
much higher crowding, yet allow for only one type of
AA building block to be sequentially connected, bringing
about fairly low synthesis rates [19, 22, 23]. Even though
first systemic ultra-dense arrangements (displaying 2.1
million overlapping 4-12mers) have only recently been
pioneered [24, 25], recombinant peptide chips could def-
initely obliterate some of above-mentioned bottlenecks.
To this end, we evaluated overall performance, practical
diversity as well as throughput of recombinant peptide
chips in a test screen against Streptavidin, and evaluated
isolated hits with biochemical and biophysical methods.
From our data we conclude that this conceptually simple,
innovative technique could deliver further flexibility to
basic and applied research. The underlying experimental
workflow is summarized in Figs. 1 and 2d, and apparent
strengths and limitations of this method are highlighted in
table 1.
Methods
Subcloning of test constructs
Templates for Strep-tag I (5′-ggggacaagtttgtacaaaaaagca
ggcttg-GCTTGGCGTCACCCGCAGTTCGGTGGTTGA-
tacccagctttcttgtacaaagtggtcccc-3′) [26], Strep-tag II
(5′-ggggacaagtttgtacaaaaaagcaggcttgTGGAGCCACCCGC
AGTTCGAAAAA-TGAtacccagctttcttgtacaaagtggtcccc-3′)
[27] as well as a 12 glycine (G) linker spaced dimer




ctttcttgtacaaagtggtcccc-3′) were de novo assembled by
Eurofins MWG Operon as attB site-flanked oligonucleo-
tides, and directly recombined into Gateway® entry vector
pDONR™-zeo (life technologies™, Thermo Fisher
Table 1 Strengths and limitations of recombinant peptide chips
Strengths of recombinant peptide chips
• Peptide libraries are created via recombinational cloning (low
frequency of background colonies; maintenance of pre-defined orien-
tation/reading frame; high cloning efficiency).
• Design ranges from entirely random peptide collections to
customized content (soft randomization; scaffold-based).
• Peptide lengths are not limited as is still the case for state-of-the-art
chemical on-chip synthesis, particle-based printing or chemically pre-
manufactured peptide spotting.
• Growth, induction and lysis of library-transformed E. coli clones all
takes place on a single nitrocellulose membrane.
• Evaporation or merging of spots is not a major concern.
• The technique is conceptually facile, robust, cost-effective, sensitive,
and easily (up-)scalable; fast turnaround times.
• Has many promising applications, e.g.: epitope mapping, alanine
substitutions, replacement studies, truncation scans, positional/
scrambled peptide library screening, along with unbiased
examinations without any a priori knowledge.
• Limited throughput can be compensated by massive parallelization
(applying e.g. elaborate pooling schemes).
• Extracted hits are immediately available as clones.
• Integration of controls for quality estimation, affinity assessment, and
inter-blot normalization is possible.
• ‘Cell-free’ nature increases the chance of confirming hits with usual
methods (FP, SPRI, Western Blot, Co-IP, etc.).
Limitations of recombinant peptide chips
• At present reachable density (resolution) represents an only sparse
sampling of the theoretically possible combinatorial random
(nonamer/hexamer) peptide library diversity.
• Number of peptides that can be screened in a single approach is
several orders smaller than feasible in typical yeast two-hybrid (Y2H)
or phage display settings.
• Technical equipment for robotic clone picking, reagent dispensing
and/or clone arraying (printing) might be needed (depending on the
desired throughput rate).
• Currently only evaluated for moderate and higher affinity (strong)
binding strengths, not for weak interactors.
• Incorporation of modified or non-proteinogenic (synthetic) segments
during chip compilation is not possible.
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Scientific). Resultant constructs were shuttled into bacter-
ial expression vector pDEST™15 (glutathione S-transferase
GST fusion plasmid, Thermo Fisher Scientific). Inserts were
sequence-verified (ABI PRISM™ Big Dye Terminator Cycle
Sequencing Ready Reaction Kit, Applied Biosystems).
Acquisition of recombinant Streptavidin/StrepTactin
Recombinant Streptavidin and/or StrepTactin proteins,
in either unconjugated format (for fluorescence polarization
assays) or with horseradish peroxidase (HRP) or Europium
labels, were purchased from Thermo Fisher Scientific,
BioRad or Perkin Elmer, respectively.
Peptide library construction
Templates for linear (5′-aaaaagcaggcttg[NNK]6/9TAAtacc
cagctttct-3′) or cyclically constrained (5′-aaaaagcaggcttg
TGT[NNK]6/9TGTTAAtacccagctttct-3′) hexamer or non-
amer peptide libraries were ordered at Microsynth AG,
and equipped on both ends with full recombinase rec-
ognition sites in the course of a standard PCR reaction
(attB1-forward: 5′-ggggacaagtttgtacaaaaaagcaggcttg-3′;
attB2-reverse: 5′-ggggaccactttgtacaagaaagctgggta-3′;
denaturation at 94 °C for 30 s, annealing at 55 °C for
30 s, extension at 72 °C for 30 s; 40 cycles). Resultant
PCR products were directly inserted into pDONR™-zeo
by BP recombination. Two 10 μl reactions each con-
taining equimolar ratios of 150 ng insert (peptide)
DNA, 150 ng vector and 2 μl BP clonase™ II mix in 1×
TE (Tris-EDTA, pH 8.0) were incubated at room
temperature (RT, 25 °C) for 20 h. The mixture was then
pooled, purified via Illustra’s GFX™ PCR DNA and Gel
Band Purification Kit (GE Healthcare), transformed
into 2 aliquots of electrocompetent Top10 E. coli cells
(theoretical efficiency: 109 cfu/μg supercoiled DNA,
Thermo Fisher Scientific) and propagated on large
(145 mm diameter, Nunc) low salt LB agar plates sup-
plemented with 25 μg/ml Zeocin™ (Thermo Fisher Sci-
entific). Serial dilutions were in parallel plated to assess
the number of independent transformants containing
unique inserts. The next day, clones were scraped,
pooled, and plasmid DNA of resultant primary entry li-
braries prepared using the GenElute™ HP Plasmid Max-
iprep kit (Sigma Aldrich). Part of the E. coli libraries
was 1:1 supplemented with 87% glycerol and frozen at
−80 °C for long-term storage. For final generation of
screening-ready [NNK]6/9 or C-[NNK]6/9-C destination
collections, respective constructs were shuttled into
vector pDEST™15 using Gateway® LR clonase™ II Plus
mix (Thermo Fisher Scientific) according to the manufac-
turer’s protocols, except that again a 5× scale was used
and recommended proteinase K digestion was omitted
[29]. Reactions were purified by running through Illustra’s
spin columns (GE Healthcare), and transformed into
100 μl electrocompetent Top10 E. coli cells. For selection
of successfully recombined vectors, cells were plated on
10 large LB agar supplemented with 100 μg/ml ampicillin.
Transformants of two plates each were scraped from
solid-surface agar, and plasmid DNA recovered. Insert di-
versity was estimated by sequencing 30 randomly picked
clones each with vector-specific primers (pDEST15-
fw = 5′-TAATACGACTCACTATAGGG-3′, T7P-rv = 5′-
TAGTTATTGCTCAG-CGGTGG-3′).
Recombinant peptide chip assembling and screening
Competent E. coli One Shot® BL21 Star™ (DE3) cells
(Thermo Fisher Scientific) carrying the gene for T7
RNA polymerase under control of isopropyl β-D-1-thio-
galactopyranoside (IPTG)-inducible lacUV5 promotor
were transformed with respective expression libraries,
and plated onto large square Q-trays. Individual colonies
were robotically picked (QPix2xt, Genetix) into suitable
384 well plates containing liquid LB medium supple-
mented with 100 μg/ml ampicillin, and cultivated over-
night at 37 °C. Alternative route was to directly split
appropriately diluted (as confirmed by plating onto LB-
amp agar plates) transformation reactions (after 1 h re-
covery in antibiotics-free SOC medium) into 384 well
plates via a programmable Flexdrop Precision Reagent
Dispenser (Perkin Elmer). The next day, clones were ro-
botically arrayed onto a 0.45 μm pore size PROTRAN™
nitrocellulose sheet (Whatman) cut in the form of the
original masterplate, applying a 1 × 1, 5 × 1, 5 × 5, or
Fig. 1 Experimental workflow
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10 × 10 pattern (such that each clone or pool is gridded
in 1, 5 or 25 or 100 replicates each). Following a 6 to 8 h
incubation interval on top of solid LB at 30 °C, peptide
expression was achieved by transferring these membrane-
imprinted clones onto LB agar plates supplemented
with 1 mM IPTG, followed by a 2 h incubation interval
at 37 °C. Cells were then directly lysed via transfer into
a Tris-buffered saline (TBS) solution containing 0.05%
Tween-20 and 3% blotting-grade milk powder. Mem-
branes were in refined dot-blot reminiscent procedure
challenged with (horseradish peroxidase) HRP- or
Europium labeled Streptavidin (in 1:1000 to 1:5000 di-
lution in TBS-0.05% Tween) for 1 h at RT, washed 3
times in TBS-0.05% Tween, and scanned with either a
ChemiDoc imaging system (Quantity One® analysis
software, BioRad) after exposure to Immobilon™ Western
chemiluminescent substrate (Millipore, Merck), or directly
with a prototypic SpectraMax® Paradigm® multi-mode de-
tection Platform (ScanLater™ Western Blot Detection
Cartridge, Molecular Devices).
Fluorescence polarization (FP)
FP assays were performed in ES2 buffer (100 mM potas-
sium phosphate pH 7.4, 100 μg/ml bovine γ globulin,
0.02% NaN3), applying 80 μl reaction volumes per black-
bottomed 384 microtitre plate well (Nalge Nunc). 20 nM
(corresponding to circa 20,000 fluorescence counts) of
5’FAM-labeled Strep-tagI (synthesized by GenScript
Inc.), Strep-tag II or any novel hit were incubated with
rising concentrations of Streptavidin/StrepTactin protein
(in triplicates each) for at least 2 h at RT (or preferably o/n
at 4 °C) to ensure binding equilibrium. Fluorescence
emission (535 nm) intensities from both parallel and
perpendicular orientations were after excitation at 480 nm
measured in a DTX Multimode Detector (Beckman
Coulter Genomics), checked for absence of abnormal
intensity changes (that might result from solvent
interference), and polarization values (expressed as
millipolarization mP units) calculated via the formula
mP = 1000(Is-GIp)/(Is + GIp), where G represents the
G factor (= Is/Ip, settled as 0.650 for this study). Data
were analyzed by Graphpad Prism 5 software, and the
dissociation constant Kd calculated by non-linear re-
gression (sigmoidal dose-response curve fitting).
Bio-layer interferometry (BLI) binding kinetics
Binding between Streptavidin and Strep-TagII, B5 or
F14.5 were in relation to a negative control peptide
(5’FAM-CLNSVAGGG) analyzed on ForteBio’s BLItz®
system. After recording of the primary baseline for 30 s
in ES2 buffer, hydrated Streptavidin-coated biosensors
were loaded with chemically synthesized peptides, and a
potential increase in BLI signal measured for 2 min. Dis-
sociation was assessed by transferring the loaded
biosensor to a tube containing buffer only. Affinities
(Kd) were calculated using the embedded BLItzPro 1.2
software.
Fusion of chip-derived hits B5 and F14.5
Templates for 12G–spaced dimeric F14.5 (5′-aaaaagc
aggcttgTGTTCGGGGAGTTAT-GGGTCGTGTggtggtggt
ggtggtggtggtggtggtggtggtggtTGTTCGGGGAGTTATGG
GTCGTGTTAAtacccagctttct-3′) and in analogous fash-
ion for B5 were ordered at Microsynth AG and amplified
with attB primers. After subcloning in pDONR™-zeo and
further in pDEST™15, any observable change in interaction
strength was evaluated on recombinant peptide chip level
in relation to enclosed Strep-tagII and Dim12G control
constructs.
Recombinant protein production and Western Blot
analysis of B5/F14.5 tagged S. aureus ClfB
Primers for C-terminally equipping an exemplary 38 kDa
S. aureus ClfB fragment (SAV2630, NP_373154, [30]) with
Strep-tag I (Clfb-fw = aaaaagcaggcttgAGTTTAGCTGT
TGCTGAACCGG; rv = 5′-gtacaagaaagctgggtaTTAacca
ccgaactgcgggtgacgccaagcATTTACTGCTGAATCACCAT
CAGC-3′, Strep-tag II (rv = 5′-tacaagaaagctgggtaTTAttttt
cgaactgcgggtggctccaATTTACTGCTGAATCACCATCAG
C-3′, F14.5 (rv = 5′- gtacaagaaagctgggtaTTAacacgaccca
taactccccgaacaATTTACTGCTGAATCACCATCAGC-3′
and B5 (rv = 5′-GTACAAGAAAGCTGGGTATTAgaaagg
ggcctgcggatgagaaacATTTACTGCTGAATCACCATCAG
C-3′ were designed. After BP recombination of resultant
PCR-products in pDONR™-zeo, inserts were recombined
in pDEST™17 (attaching an additional N-terminal 6xHIS-
tag). For small-scale purification, ClfB from soluble, IPTG
induced supernatants was captured on pre-equilibrated
magnetic Streptavidin coated Dynabeads® (Thermo Scien-
tific) in PBS on a rotary shaker, washed 4 times in PBS
containing 0.1% bovine serum albumin, eluted by harsh
boiling for 2 min in 1× SDS sample buffer, and subjected
to 12% SDS-PAGE electrophoresis. Following transfer to
nitrocellulose and blocking in 3% non-fat milk in TBS-
0.05% Tween for 1 h at RT, membranes were probed ei-
ther directly with HRP-Streptavidin / StrepTactin (1:1000)
or with an α-6xHIS HIS (SantaCruz) / HRP-α-mouse anti-
body (1:10,000, Agilent Technologies) combination. For
dot blot analysis, 1 μl of total cell lysates, soluble superna-
tants, and recovered eluates were manually spotted each.
Results
Both novel and cognate Streptavidin binders can be
extracted from recombinant peptide chips
Screening parameters were first of all optimized: signal-
to-background ratios and realizable detection limits were
assessed by analyzing the associations between published
Strep-tagI and II peptides (as well as 12G linker spaced
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dimer derived thereof ) and either commercially available
HRP- or fluorescence labeled Streptavidin. Our prelim-
inary screening of a recombinant test peptide chip con-
tent assembled from respective control strains (Fig. 2)
permitted us to clearly distinguish both moderate
(Strep-tagI and II) and higher affinity (Dim12G) binders
in comparison to the enclosed negative control, pointing
to the overall practical feasibility of such an approach.
We next further optimized E. coli growth times (from 0
to 24 h at 2 different temperatures), induction intervals,
critical cell densities required, printing conditions, lysis
and detection conditions, etc. (Fig. 2). Incubation of the
imprinted membranes for 6 to 8 h at 30 °C on top of
LB-amp plates prior to IPTG induction - but in no case
overnight at 37 C because of excessively accumulating
bacterial biomass - yielded acceptable results for Strep-
tag constructs in comparison to empty vector reference
(for both HRP and Europium detection). Despite leaky
basal expression and hence observable differences even
at time point 0 (lysis of clones directly after arraying),
IPTG induction definitively triggered increased peptide
expression levels, thereby delivering more consistent re-
sults. Our applied low concentration of 0.05% Tween-20
as weak non-ionic detergent lysed enough bacterial cells
to release sufficient recombinant material for immediate
immobilization, but simultaneously maintained the ability
of fluorescent control proteins to emit light (data not
shown), suggesting that it does not denature peptides/
proteins but instead preserves their native (−like) con-
formation. Strep-tagI, Strep-tagII and Dim12G were fur-
ther exploited for fine-tuning printing densities (5 × 5
pattern for 25 replicates, to at present maximally 100 spots
on the area of a single 384 microtiter plate well), and were
enclosed as internal controls in subsequent chip assembly
efforts for standardization, quality estimation, affinity as-
sessment, as well as inter-blot normalisation.
Bona fide performance in large-scale discovery screen-
ing was in a next step addressed by assembling random
peptide chips from comprehensive random recombinant
peptide libraries, all prepared by in-house up-scaled re-
combinational cloning procedures [29]. These libraries
were designed to carry either a linear or a cyclically con-
strained degenerate NNK triplet configuration (where N
denotes an equimolar 25% mixture of all 4 deoxynucleo-
tides; and K represents a 50% balanced mix of each thy-
mine and guanine), thereby incorporating all 20 natural
AA (redundant codon reduction from 64 to 32) yet merely
one single amber TAG stop codon [31]. Transformation
efficiencies, overall insert diversities, and lack of apparent
bias were determined for all independently cloned entry
and destination resources (Fig. 3a) by counting the num-
ber of E. coli clones grown on antibiotics-supplemented
LB agar plates, followed by sequencing 100 randomly
picked single E. coli clones each. Following the above-
established workflow, 2 hits (retrieved from the corre-
sponding position in the original microtiter masterplate;
Fig. 2 Recombinant peptide chip optimization. a Assessment of best E. coli growth intervals for consistent chip performance. A series of E. coli
cells transformed with either Strep-tag constructs or empty vector were imprinted on nitrocellulose, grown thereon for the specified period, then
exposed to IPTG, and subsequently lysed. Released peptides were analysed for their interaction with HRP-labeled Streptavidin. b Signal intensities
(and so a rough estimation of affinities) between Strep-tagII and Dim12G were evaluated in relation to empty vector control, as indicated. Different
peptide spot numbers per single standardized microtiter plate well are compared. c Consistent pin performance and maximal detection sensitivity were
assessed by spotting a dilution series of biotinylated test protein. d Steps required for recombinant peptide chip assembly
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identification via sequencing of isolated plasmid DNA)
could be selected.
Candidate B5 (VSHPQAPF, premature stop) was un-
covered from altogether screened 215,040 random pep-
tides arbitrarily selected from 12.6 × 106 clones of linear
nonamers. F14.5 (C-SGSYGS-C), on the other hand, was
extracted from 261,120 spotted random cyclic hexamers
(11.2 × 106 combinations) by directly dispensing diluted
transformation mixes and re-analysing positive pools on
single-clone level. The success rate was therefore 2
binders from 476,160 screened recombinant peptides.
Since Dim12G, a fusion of Strep-tagI and Strep-tagII
monomers, performs superior in comparison to a single
monomer, our identified candidates B5 and F14.5 were
subsequently dimerized (spaced by an analogous 12
glycine linker), and investigated for increased affinity
(Fig. 4b). Whilst the HRP-Streptavidin mediated signals
remained fairly constant for both F14.5 mono- and dimer,
B5 monomer functioned slightly better than its merged
counterpart. In both cases we could not increase affinity
by linear dimerization, indicating that our hits rather func-
tion in a monomeric state.
Chip-derived hits can be confirmed in independent
assays, underscoring target binding specificity
We confirmed chip-derived hits B5 and F14.5 in cell-free
assays (see Fig. 5), ruling out false-positives (unspecific
‘sticky’ binders). An FP assay - conceptually based on rota-
tional differences between labeled peptides free in solution
versus complexed to an interactor - was arranged for
chemically synthesized 5’FAM-labeled peptides Strep-tagI,
Strep-tagII, B5, and F14.5. We monitored expected dose-
dependent increases in polarization with increasing
amounts of recombinant protein for Strep-tagI (Kd= 2.75μM
for Streptavidin) and StrepTag II (Kd of 13.26 μM for Strep-
tavidin; literature-conform superior Kd of 0.43 μM for
StrepTactin). Saturation binding could also be observed for
B5 (Kd = 4.16 μM for StrepTactin) as well as F14.5
(Kd = 44.29 μM). Despite differences in slopes and ampli-
tudes, both interaction potential and target specificity were
in this way evaluated. Secondly, label-free biolayer interfer-
ometry (BLI) was measured on a disposable Streptavidin-
coated biosensor which we exposed to respective peptides,
thereby leading to an increase in optical thickness at the tip
and, simultaneously, a real-time measurable wavelength
shift (interference pattern of the reflected light) propor-
tional to binding. The calculated Kd values were 25.4 μM
for the Strep-tagII positive control (initially very fast bind-
ing; to a lesser extent also observed in other buffers),
105 μM for F14.5, and 79.5 μM for B5. Although peptide
solvent, applied assay buffer and the fact that only a single
analyte concentration was tested admittedly influence de-
tected outcomes, achieved results appear consistent with
above data.
Further engineering efforts might transform extracted
hits into suitable binders
In order to evaluate whether B5 or F14.5 might be directly
used as novel Western Blot detection or even as affinity
purification agents, we equipped an exemplary 6xHIS-
Fig. 3 Performance of literature-validated Strep-tags in our recombinant peptide chip setup, and comparison of target binding affinities to two
novel chip-derived binders. a Nature and diversity of random peptide expression libraries applied for this study. b Detailed comparison of both
known (see discussion section) and novel Streptavidin/StrepTactin binders. SBP and Nanotags (highlighted in light grey) have not been included
in the present study. WB, Western Blot
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tagged test protein (S. aureus clumping factor ClfB;
chosen because it can be produced in soluble form
and acceptable yield) with respective peptides (Fig. 6).
Comparable signals were observed on both dot-blot
(HRP-StrepTactin) and Western Blot (HRP-Streptavidin)
level for Strep-tagI and Strep-tagII in crude lysed cell
extracts or soluble supernatants (obtained thereof after
centrifugation clearance). HPQ-containing B5 could be
successfully detected as well, albeit at reduced intensity.
We next tried to affinity-purify all 4 tagged proteins (in
relation to unmodified ClfB, carrying solely a 6xHIS-tag)
by magnetic Streptavidin beads under physiological buffer
conditions. Consistent with above results, B5 performed
acceptably (yet poorer than Strep-tagsI and II), whilst
F14.5-tagged ClfB could only be detected in an α-6xHIS
antibody control blot.
Discussion
Recombinant peptide chips take advantage of directly
growing, inducing and lysing library-transformed E. coli
clones on a single nitrocellulose membrane for subse-
quent screening with labelled proteins or compounds,
thereby constituting a HTP-compatible alternative to
presently available synthetic chemistry setups. We have
previously already demonstrated the theoretical feasibil-
ity of proposed tactic by mapping the roughly specified
epitope of a commercial antibody against vitamin D3
receptor by screening 2304 overlapping peptides to a 27
AA encompassing continuous stretch [32]. Many meth-
odical aspects have since then been fine-tuned (Fig. 2),
amongst them in-depth evaluation of most optimal E.
coli growth and IPTG induction times/temperatures,
printing densities (25 to maximal 100 spots per peptide),
etc. In continuation, the present work now examines
recombinant peptide chips under optimized conditions
(e.g., signal-to-background ratios, interactor affinity
ranges, practically reachable density) by basically exploit-
ing the well-described interactions between Streptavidin
and short artificial Strep-tag I (AWRHPQFGG, published
KDs of 0.7–37 μM, strongly dependent on accomplished
assay type), Strep-tag II (WSHPQFEK, KD of 13–72 μM)
as well as a 12G–linker spaced dimer as internal controls
and reference (summarized in Fig. 3). Strep-tag I specific-
ally binds to a proteolytically truncated ‘core’ version of
Streptavidin by occupying the same pocket where biotin
as the natural ligand with a dissociation constant around
10−15 M normally gets non-covalently complexed [26, 33,
34]. It was isolated from a genetic library as novel affinity
reagent for the purification of fusion proteins on Streptavi-
din matrices at high purity and maintained functionality/
bioactivity. Systematic optimizations have over the years
yielded Strep-tag II (and subsequent introduction of a
dimeric ‘twin’ tag) which exhibits not only higher intrinsic
affinity towards StrepTactin, but also permits greater flexi-
bility in choice of attachment site (N- as well as C-terminal
fusion) [28, 34]. Further parallel in vitro selection attempts
have parenthetically brought about the 38 AA encompass-
ing SBP-tag with an equilibrium dissociation constant of
2.5 nM [35, 36], and the 9mer (17 nM) or 15mer (4 nM)
Nano-tags with their nanomolar affinities [37].
We screened Streptavidin (mainly chosen because it
shows - as widely applied purification and immunoassay
detection reagent - low unspecific binding properties,
and has been successfully applied in several previous
Fig. 4 Uncovery of novel Streptavidin binders by recombinant
peptide chips. a Excerpt of a random peptide chip (5 technical
replicates each), resulting in the discovery of F14.5. Positive controls
were included for simultaneous semi-quantitative evaluation of
binding strengths. An in parallel performed GST-blot reveals
relatively homogenous peptide expression levels. b Dimerisation
of B5 and F14.5, analyzed by recombinant peptide chip
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phage and mRNA display selections [38]) against our re-
combinant peptide chips. The latter were built from either
linear or disulfide-bond constrained cyclic libraries. Re-
spective peptide populations (Fig. 3a) consisted on average
of 6 × 106 to more than 1 × 107 diverse single clones (not
taking into account point mutations, frameshifts or
premature stops that might be caused by proofreading
activity-lacking Taq polymerase and the applied PCR
conditions, thereby further enrichening the repertoire).
Despite this substantial combinatorial diversity (which
again is proportional to the probability of uncovering
peptides with desired properties [39]), this number still
represents an only sparse sampling of the theoretically
possible combinatorial library diversity. The theoretical
sequence space is up to 206 or 209 inserts, for an ex-
haustive hexamer or nonamer library, respectively. At
present, a maximum of 38,400 spots can be displayed
on a standard microtiter-plate sized membrane (under
optimized conditions, with pin based usual DNA/pro-
tein spotters). This number is several orders smaller
than feasible in typical Y2H or phage display screening
sceneries, and represents only a tiny fraction of the theor-
etical possible diversity of a nonamer/hexamer library.
This challenge was compensated by parallelization, i.e., by
performing either many simultaneous screens, or by
initiating elaborate pooling schemes (dispensing of
Fig. 5 Re-evaluation of chip-derived Streptavidin binders in complementary setups. a In vitro fluorescence polarization assays using constant
amounts of 5’FAM labeled (chemically synthesized) peptides plus increasing concentrations of recombinant protein. Data are reported as mean
from 3 independently performed measurements. Standard deviation was below 15% for all values. b Binding kinetics (association of pre-determined
amounts 5’FAM labeled peptides to Streptavidin biosensors) were measured via biolayer-interferometry. Kd values as calculated from the BLItz
Pro software are listed
Fig. 6 Functional analysis of hit peptides as putative affinity/purification reagents. a Schematic illustration of underlying cloning procedure.
b S. aureus clumping factor was C-terminally tagged with either Strep-tag I, Strep-tag II, F14.5 or B5, as indicated, and shuttled together with
the original (unmodified) construct in pDEST™17. Recombinant protein expression (total lysate; S: soluble supernatant) and subsequent ClfB
(37 kDa) protein purification on magnetic Streptavidin beads (E: eluate) were detected on dot blot as well as Western Blot level (12.5% SDS-PAGE),
applying either HRP-labeled Streptavidin/StrepTactin or an α-6xHIS control antibody. Molecular mass standards (M) are indicated on the left
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appropriately diluted transformation mixes) that initially
test pools, e.g. 10 clones per array position first (which in-
creases the throughput 10 times) and subsequently re-
analyse positive pools on single-insert level. In doing so, 2
Streptavidin binders could be successfully uncovered, i.e.,
candidate B5 from a representative number of 215,040 lin-
ear nonamers, and F14.5 from 261,120 tested cyclically
constrained hexamers. This number is still far below cell-
based screening techniques, however completely cell-free
and based on a biochemical principle, which increases the
chance that first hits are confirmed with usually used con-
firmation methods (FP, SPRI, WB, Co-IP, etc.). Practically
considered, a number of ~500 k different peptides repre-
sents an impressive and useful diversity for screening ap-
proaches. Candidate B5, of note, contains the typical HPQ
core consensus motif characteristic for biotin mimetics,
underscoring that recombinant peptide chips built from
such random libraries indeed constitute a source for spe-
cific, functional target binders [40]. The lower affinity
compared to the original Strep-tags for both Streptavidin
and StrepTactin can be explained by the flanking AA resi-
dues that alter the conformation of the central HPQ
tripeptide. F14.5 with its attached cysteine residues, in
contrast, does not contain any known pattern [38, 41], and
can hence be considered as a new peptide with a different
binding mechanism.
The specificities of B5 and F14.5 were finally re-
evaluated in complementary experimental setups. For
technical confirmation, we used fluorescence polarization
and bio-layer interferometry, which delivered also affinity
data. A functional evaluation was based on recombinant
expression and affinity purification of a tagged test protein.
The measured dissociation constants of B5 and F14.5
(4.16 μM and 44.29 μM for StrepTactin in FP studies
versus 79.5 μM and 104.6 μM in bio-layer interferometry
kinetic analyses) further corroborated target binding speci-
ficities, albeit at significantly lower affinities compared to
the enclosed Strep-tag positive controls. B5 (attached to
ClfB test protein) could on Western Blot level be success-
fully detected in crude bacterial cell lysates, and proved
even functional in affinity purification of ClfB on Strepta-
vidin beads. These latter 2 applications were, in contrast,
not feasible with F14.5, indicating most likely sterical or
conformational problems of this tag in fusion to the test
protein, calling for further engineering/maturation efforts
(inclusion of a linker, analysis of other test proteins etc.).
Conclusion
Our recombinant peptide chip technology couples the
merits of recombinant protein technologies and com-
binatorial cloning strategies with high-density peptide
chip assembly and high-throughput screening (see table 1).
Features like conceptual straightforwardness, robustness
and cost-effectiveness along with sensitivity, consistency as
well as fast turnaround times equip this scalable, easily
upscaling feasible setup with promising applications.
Examples range from epitope mapping (wherein a protein
under study is meticulously split into biologically active
fragments) to systematic alanine substitutions, replace-
ment studies (for investigating the contribution of distinct
AAs and their possible exchanges), truncation scans
(highlighting the minimum essential length of a functional
peptide) and finally positional or scrambled (carrying
permutations on the original sequence) peptide library
screenings. Unbiased examinations of comprehensive
peptide collections without any a priori knowledge, or, of
an entire proteome translated into sets of overlapping
peptides might yield unexpected associations missed in
limited throughput. On the other hand, customized con-
tent (soft randomisation of first-generation hits by introdu-
cing degeneracy via wobble codon mixtures; scaffold-based
design) can be launched without any size constraints,
enabling a further maturation of interaction strengths or
target specificities. Peptides uncovered by high-density
recombinant peptide chips might therefore offer new pos-
sibilities for diagnostic, therapeutic, and basic research
purposes. In summary, we could here present the con-
struction and practical application of recombinant peptide
chips in a large scale approach which is neither technically
nor economically feasible by synthetical peptide strategies.
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